CHF Solutions Expands its Patent Portfolio with Four Applications for Innovations for Aquapheresis Therapy
January 30 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced the filing of four
patent applications with the United States Patent and Trademark
Office (USPTO) to protect new innovations for use in aquapheresis
therapy and further strengthen the company’s intellectual property
protection for its Aquadex FlexFlow® system.
“At CHF Solutions, we are dedicated to the
development of innovations to change the lives of patients
suffering from fluid overload,” said John Erb, chairman and CEO of
CHF Solutions. “We believe that the innovations captured in these
pending patent applications will improve the delivery of
aquapheresis therapy.”
The first application includes multiple potential
new features and improvements to the diagnostic and ultrafiltration
capabilities of the Aquadex FlexFlow system, which, if incorporated
into the product, would be designed to improve usability for
healthcare providers and guide therapy for optimum patient fluid
balance. The second application is based on the company’s design
for a wearable device intended to assist in maintaining peripheral
venous blood flow access in the arm during ultrafiltration
treatment. The third application involves a wearable medical device
designed to promote venous return. The fourth application involves
a device designed to assess circulatory status during therapy.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical
device company dedicated to changing the lives of patients
suffering from fluid overload through science, collaboration, and
innovative technology. The company is focused on developing,
manufacturing, and commercializing the Aquadex FlexFlow system for
ultrafiltration therapy. CHF Solutions is a Delaware corporation
headquartered in Minneapolis, Minnesota with wholly owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About Aquadex FlexFlow System
The Aquadex FlexFlow system is a clinically proven
therapy that provides a safe, effective, and predictable method of
removing excess fluid from patients suffering from fluid overload.
The Aquadex FlexFlow system is indicated for temporary (up to eight
hours) ultrafiltration treatment of patients with fluid overload
who have failed diuretic therapy, and for extended (longer than 8
hours) ultrafiltration treatment of patients with fluid overload
who have failed diuretic therapy and require hospitalization. The
company has submitted an application to the FDA requesting for
510(k) clearance of the Aquadex FlexFlow system to include
pediatric patients who weigh 20kg or more. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be
considered forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including without
limitation, the ability of the design features contained in the
patent applications to improve product performance.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024